Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 116 participants.

Also called NCT02933788

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 116 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02933788
Other papers using this trial's data
  • Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular Disease Endocrinology and metabolism (Seoul, Korea), 2022-04 DOI, PubMed 35381686, PMC9081299 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02933788. Randomized; no masking; primary purpose prevention. Start 2016-10 (registry gives no type); primary completion 2016-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Cilostazol
Intervention (Drug)
Acetylsalicylic acid
Lead sponsor
Kangbuk Samsung Hospital (class: other)
Collaborator
Asan Medical Center (class: other)

Record details

Record id
cardio:ct-nct02933788
Content hash
2d293340af9a211dc1f5aa3d97d57a7b042b1b61719fde4cfd7e5c6774a63d4d